NASDAQ:PRAH - PRA Health Sciences Stock Price, Forecast & News

PRA Health Sciences trades on the NASDAQ under the ticker symbol "PRAH."

PRA Health Sciences Inc (NASDAQ:PRAH) released its earnings results on Wednesday, October, 30th. The medical research company reported $1.32 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $1.29 by $0.03. The medical research company earned $780.70 million during the quarter, compared to analysts' expectations of $771.64 million. PRA Health Sciences had a return on equity of 27.73% and a net margin of 8.00%. The business's revenue was up 8.8% on a year-over-year basis. During the same period in the prior year, the business posted $1.13 EPS. View PRA Health Sciences' Earnings History.

PRA Health Sciences is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for PRA Health Sciences.

PRA Health Sciences updated its FY19 earnings guidance on Wednesday, October, 30th. The company provided earnings per share (EPS) guidance of $5.07-$5.12 for the period, compared to the Thomson Reuters consensus estimate of $5.07. The company issued revenue guidance of $3.02-$3.10 billion, compared to the consensus revenue estimate of $3.06 billion.

10 brokers have issued 12 month price targets for PRA Health Sciences' stock. Their forecasts range from $100.00 to $123.00. On average, they anticipate PRA Health Sciences' share price to reach $116.44 in the next year. This suggests a possible upside of 9.9% from the stock's current price. View Analyst Price Targets for PRA Health Sciences.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PRA Health Sciences in the last year. There are currently 6 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for PRA Health Sciences.

Media headlines about PRAH stock have trended positive this week, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. PRA Health Sciences earned a coverage optimism score of 3.0 on InfoTrie's scale. They also assigned media coverage about the medical research company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the next several days. View News Stories for PRA Health Sciences.

PRA Health Sciences saw a increase in short interest in December. As of December 31st, there was short interest totalling 2,090,000 shares, an increase of 29.8% from the December 15th total of 1,610,000 shares. Based on an average daily trading volume, of 498,200 shares, the days-to-cover ratio is presently 4.2 days. Approximately 3.3% of the company's stock are short sold. View PRA Health Sciences' Current Options Chain.

Some companies that are related to PRA Health Sciences include Incyte (INCY), EXACT Sciences (EXAS), Icon (ICLR), Charles River Laboratories Intl. (CRL), Syneos Health (SYNH), Exelixis (EXEL), BTG (BTGGF), Medpace (MEDP), National Research (NRC), Intrexon (XON), Sorrento Therapeutics (SRNE), Auxly Cannabis Group (CBWTF), STARPHARMA HOLD/S (SPHRY), Luna Innovations (LUNA) and Pieris Pharmaceuticals (PIRS).

Based on aggregate information from My MarketBeat watchlists, some companies that other PRA Health Sciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Adobe (ADBE), Paypal (PYPL), Applied Materials (AMAT), Lam Research (LRCX), Veeva Systems (VEEV), Netflix (NFLX), Arista Networks (ANET) and salesforce.com (CRM).

(PRAH) raised $306 million in an initial public offering on Thursday, November 13th 2014. The company issued 17,000,000 shares at $18.00 per share. Jefferies, Citigroup, KKR, UBS Investment Bank, Credit Suisse and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.

PRA Health Sciences' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Reilly Financial Advisors LLC (0.18%), Assenagon Asset Management S.A. (0.16%), Artemis Investment Management LLP (0.15%), Scout Investments Inc. (0.15%), Gateway Investment Advisers LLC (0.05%) and Three Peaks Capital Management LLC (0.04%). Company insiders that own PRA Health Sciences stock include Fund Holdings LP Kkr and Pra Investors LP Kkr. View Institutional Ownership Trends for PRA Health Sciences.

PRAH stock was sold by a variety of institutional investors in the last quarter, including Artemis Investment Management LLP, Gateway Investment Advisers LLC, Sciencast Management LP, Scout Investments Inc., Nisa Investment Advisors LLC, State of Alaska Department of Revenue and New England Research & Management Inc.. View Insider Buying and Selling for PRA Health Sciences.

PRAH stock was acquired by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Three Peaks Capital Management LLC, Reilly Financial Advisors LLC, Fulton Breakefield Broenniman LLC, FNY Investment Advisers LLC, Advisors Capital Management LLC and Louisiana State Employees Retirement System. View Insider Buying and Selling for PRA Health Sciences.

Shares of PRAH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PRAH stock can currently be purchased for approximately $105.99.

PRA Health Sciences has a market capitalization of $6.70 billion and generates $2.87 billion in revenue each year. The medical research company earns $153.90 million in net income (profit) each year or $3.93 on an earnings per share basis. PRA Health Sciences employs 16,400 workers across the globe.View Additional Information About PRA Health Sciences.

The official website for PRA Health Sciences is http://www.prahs.com/.

PRA Health Sciences' mailing address is 4130 PARKLAKE AVENUE SUITE 400, RALEIGH NC, 27612. The medical research company can be reached via phone at 919-786-8200 or via email at [email protected]